IGF-1 LR3
IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor 1)
A modified, three-times-more-potent version of IGF-1 that acts directly on muscle tissue to promote both muscle fiber growth and new muscle cell formation.
IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor 1) is a synthetic, modified version of the naturally occurring hormone IGF-1. It is an 83 amino acid peptide that has been engineered to be more potent and longer lasting than the native hormone. The modifications are twofold: an arginine amino acid replaces a glutamic acid at position 3, and 13 additional amino acids are added at the N-terminus. These changes dramatically alter its behavior in your body.
Natural IGF-1 is produced primarily in your liver in response to growth hormone stimulation. It normally circulates through your body bound to insulin-like growth factor binding proteins (IGFBPs) which regulate its activity and limit its half-life to about 12 to 15 hours. IGF-1 LR3's modifications give it very low affinity for these binding proteins, meaning it circulates in a much more active, unbound state. The result is approximately 3 times greater potency than native IGF-1 and a significantly extended half-life of 20 to 30 hours.
Unlike HGH and secretagogues like CJC-1295 and Ipamorelin which work indirectly by stimulating your pituitary, IGF-1 LR3 acts directly on target tissues. It does not require conversion or processing by the liver. This direct action produces more consistent and predictable effects but also means it bypasses your body's natural feedback systems entirely. IGF-1 LR3 is not FDA approved for any medical use and should not be stacked with GH secretagogues because elevated IGF-1 triggers somatostatin release, which blocks secretagogue signals by up to 86 percent.
How It Works
IGF-1 LR3 works by binding to and activating the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor found on cells throughout your body. When IGF-1 LR3 binds to this receptor, the receptor undergoes autophosphorylation, which activates two major signaling pathways. The PI3K-Akt pathway promotes protein synthesis, cell survival, and glucose uptake. The MAPK pathway stimulates cellular proliferation and differentiation. These pathways work together to produce IGF-1 LR3's anabolic effects.
IGF-1 LR3 promotes muscle growth through two distinct processes that set it apart from most other anabolic compounds. The first is hypertrophy, which means increasing the size of existing muscle fibers through enhanced protein synthesis and positive nitrogen balance. The second is hyperplasia, which means stimulating the proliferation of satellite cells (muscle stem cells) that can form entirely new muscle fibers. This hyperplasia effect is sometimes called true hypertrophy because it involves creating new cells rather than just enlarging existing ones. Most anabolic compounds only work through hypertrophy.
Because IGF-1 LR3 has very low affinity for binding proteins, it remains active in circulation for 20 to 30 hours rather than being quickly bound up and cleared. This extended activity window means each dose produces sustained effects on target tissues. IGF-1 LR3 also has insulin-like effects and can improve glucose transport into muscle cells, which supports better nutrient utilization and glycogen storage. However, this same property creates a significant risk of hypoglycemia that requires careful management.
Potential Benefits
Muscle Cell Proliferation (Hyperplasia)
IGF-1 LR3 activates satellite cells and promotes the formation of new muscle cells, not just the enlargement of existing ones. This unique mechanism can produce muscle growth beyond what is achievable through hypertrophy alone. The activation of muscle stem cells enables both the repair of damaged muscle and the formation of entirely new muscle fibers, a capability that most anabolic compounds do not possess.
Enhanced Muscle Growth (Hypertrophy)
IGF-1 LR3 increases protein synthesis and creates a positive nitrogen balance, meaning your body retains more of the protein you eat for building muscle. It enhances the uptake of amino acids into muscle cells and promotes the utilization of nutrients for muscle building. Users typically report fuller, denser muscles that develop over the course of a cycle.
Accelerated Recovery
IGF-1 promotes tissue repair and regeneration at the cellular level. This translates to faster recovery between training sessions, reduced muscle soreness, and improved healing from minor injuries. The satellite cell activation also supports repair of damaged muscle tissue, which is the foundation of the muscle building process.
Fat Loss and Body Recomposition
Elevated IGF-1 levels are associated with increased fat metabolism and improved nutrient partitioning, meaning your body directs calories toward muscle tissue rather than fat storage. Many users report simultaneous muscle gain and fat loss, achieving the coveted body recomposition effect that is difficult to accomplish with training and nutrition alone.
Improved Insulin Sensitivity
IGF-1 has insulin-like effects and can improve glucose transport into muscle cells. This supports better nutrient utilization and glycogen storage, particularly when combined with post-workout nutrition. Research has shown IGF-1 can reduce insulin requirements by up to 10 percent in diabetic patients.
Connective Tissue Repair
Research suggests IGF-1 LR3 may accelerate healing of tendons, ligaments, and other connective tissues through its effects on fibroblast activity and collagen production. This makes it of interest for injury recovery applications beyond its muscle-building properties.
Anti-Aging Potential
IGF-1 levels decline naturally with age, contributing to sarcopenia (age-related muscle loss). IGF-1 LR3 may help counteract this decline by supporting muscle preservation and regeneration in aging individuals, addressing one of the key hormonal deficiencies associated with getting older.
What the Research Shows
The structural modifications that distinguish IGF-1 LR3 from native IGF-1 have been well characterized in published research. The arginine at position 3 and 13 additional N-terminal amino acids result in retention of full pharmacological activity at the IGF-1 receptor, very low affinity for IGF-binding proteins, improved metabolic stability, approximately 3 times greater potency than native IGF-1, and an extended half-life of 20 to 30 hours compared to 12 to 15 hours for native IGF-1.
Adams published an invited review in the Journal of Applied Physiology in 2002 demonstrating that IGF-1 induces proliferation and differentiation of muscle satellite cells, enabling hypertrophic adaptations in response to mechanical overload. This supports the mechanism underlying IGF-1 LR3's unique ability to promote both hypertrophy and hyperplasia. Research in muscle wasting conditions including HIV-associated wasting and age-related sarcopenia has shown that subjects treated with IGF-1 are better able to preserve lean muscle mass.
Metabolic research has shown that IGF-1 can improve insulin sensitivity and reduce insulin requirements in diabetic patients by up to 10 percent. Clinical data also shows that IGF-1 stimulates bone formation through direct effects on osteoblasts, demonstrating significant anabolic activity and bone-protective effects. IGF-1 LR3's extended activity and enhanced potency could amplify these metabolic and skeletal benefits compared to native IGF-1.
What to Know
Hypoglycemia (low blood sugar) is the most important and most common acute side effect. Symptoms include shakiness, tremors, sweating, confusion, difficulty concentrating, weakness, and rapid heartbeat. Always have fast-acting carbohydrates available. Water retention, joint pain, headache, and injection site reactions also occur frequently.
Insulin resistance can develop with prolonged use. Do not stack IGF-1 LR3 with GH secretagogues like CJC-1295, Ipamorelin, Tesamorelin, or MK-677 because elevated IGF-1 triggers somatostatin release that blocks secretagogue signals by up to 86 percent. Combining IGF-1 LR3 with insulin is very dangerous and not recommended outside of highly supervised medical settings. Cycling of 4 to 6 weeks on followed by 4 to 6 weeks off is essential.
Do not use if you have active cancer or history of cancer, as IGF-1 promotes cell growth and proliferation which may accelerate tumor growth. Do not use with diabetes due to risk of severe hypoglycemia. Long-term concerns include organ growth at high doses over extended periods, potential for abnormal cellular proliferation, and development of antibodies with extended use. Persistent hypoglycemia, significant edema, carpal tunnel symptoms, or GI discomfort are signs to stop or reduce dose immediately.
Research References
Invited Review: Autocrine/paracrine IGF-I and skeletal muscle adaptation
Adams GR · Journal of Applied Physiology · 2002
Demonstrated that IGF-1 induces proliferation and differentiation of muscle satellite cells, enabling hypertrophic adaptations in response to mechanical overload, supporting the mechanism underlying IGF-1 LR3's effects on muscle growth through both hypertrophy and hyperplasia.
View StudyInsulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism
Fryburg DA · American Journal of Physiology · 1994
Established that IGF-1 exerts direct anabolic effects on human muscle protein metabolism, including enhanced protein synthesis and insulin-like metabolic actions on muscle tissue.
View StudyGrowth hormone and the insulin-like growth factor system in myogenesis
Florini JR, et al. · Endocrine Reviews · 1996
Comprehensive review of the role of the IGF system in muscle cell development and growth, detailing how IGF-1 promotes satellite cell proliferation, differentiation, and fusion into mature muscle fibers.
View Study